A Crossover Study to Evaluate Amantadine Steady-State Pharmacokinetics Following Oral Administration of ADS 5101, Amantadine HCl Extended Release (ER) Capsules, QD and the Amantadine HCl Immediate Release (IR) Tablets BID in Healthy Subjects.

Trial Profile

A Crossover Study to Evaluate Amantadine Steady-State Pharmacokinetics Following Oral Administration of ADS 5101, Amantadine HCl Extended Release (ER) Capsules, QD and the Amantadine HCl Immediate Release (IR) Tablets BID in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2018

At a glance

  • Drugs Amantadine (Primary)
  • Indications Neurological disorders; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 18 May 2018 Results of pooled data from 2 phase1 trial and a phase 2/3 trial assessing pharmacokinetics of ADS-5102 (Amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia, were published in the Clinical Pharmacokinetics.
    • 12 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top